IL6
ENSG00000136244
Target class
Secreted protein
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
8
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- IL6
- Gene name
- Interleukin 6
- Gene symbol
- IL6
- Previous gene symbols
- IFNB2
- Protein name
- Interleukin-6 (IL-6) (B-cell stimulatory factor 2) (BSF-2) (CTL differentiation factor) (CDF) (Hybridoma growth factor) (Interferon beta-2) (IFN-beta-2)
- IL-6
- BSF2
- HGF
- HSF
- Gene biotype
- Protein coding
- Gene family
- Interleukins|Interleukin 6 type cytokine family
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 34
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 54.44
- Tissue specificity (Gini)
- 0.667
- Tissue specificity (tau)
- 0.933
- KEGG gene identifiers
- hsa:3569
- Protein interaction confidence
- 0.826208
- Protein interaction partners
- 366
- R-HSA-1059683
- R-HSA-110056
- R-HSA-112411
- R-HSA-2559582
- R-HSA-381426
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-8853884
- R-HSA-8957275
- R-HSA-9660821
- R-HSA-9662834
- R-HSA-9958825
- End position
- 22732002
- Start position
- 22725884
- Chromosome
- 7
- Strand
- Forward
- Secreted .
- Vesicles
Publication evidence
- PubMed 11080265
- Tissue specificity (tau)
- 0.932735
- Expression inequality (Gini)
- 0.666512
Expression in transcripts per million
- Adipose - Visceral (Omentum)
- 54.44
- Lung
- 29.65
- Fallopian Tube
- 13.58
- Breast - Mammary Tissue
- 13.06
- Adipose - Subcutaneous
- 11.83
Expression in transcripts per million
- Adipose - Visceral (Omentum)54.44
- Lung29.65
- Fallopian Tube13.58
- Breast - Mammary Tissue13.06
- Adipose - Subcutaneous11.83
- Artery - Coronary11.58
- Artery - Aorta11.24
- Cells - Cultured fibroblasts8.8
- Nerve - Tibial7.69
- Colon - Sigmoid7.59
- Esophagus - Gastroesophageal Junction6
- Pituitary5.72
- Esophagus - Muscularis5.36
- Kidney - Medulla5.35
- Heart - Atrial Appendage5.28
- Thyroid5.04
- Minor Salivary Gland4.4
- Spleen3.53
- Bladder2.84
- Vagina2.44
- Colon - Transverse2.43
- Stomach2.03
- Prostate2
- Artery - Tibial1.97
- Skin - Not Sun Exposed (Suprapubic)1.87
And 29 more, listed on the interactive page.
- GO:0001781
- GO:0002384
- GO:0002446
- GO:0002548
- GO:0002639
- GO:0002675
- GO:0002690
- GO:0006953
- GO:0006954
- GO:0006959
- GO:0007259
- GO:0008284
- GO:0008285
- GO:0010573
- GO:0010574
- GO:0010575
- GO:0010628
- GO:0010718
- GO:0019221
- GO:0030168
- GO:0031175
- GO:0032722
- GO:0032731
- GO:0032733
- GO:0032755
And 47 more, listed on the interactive page.
- GO:0005576
- GO:0005788
- GO:0005896
- GO:0005125
- GO:0005138
- GO:0005515
- GO:0008083
- GO:0042802
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_IL6is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.
- cell-based: LTEA_HepaRG_IL6is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.
Biological samples
- HepaRG, cell line
Evidence sourceregulation of gene expression
Studies
- cell-based: BSK_CASM3C_IL6, is one of 14 assay component(s) measured or calculated from the BSK_CASM3C assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
Biological samples
- coronary artery smooth muscle cells, primary cell
Evidence source
Related records
Trials (140)
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
- A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
- A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
- A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
- A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
- A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
- A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
- A Pilot Trial of Clazakizumab in Late ABMR
- A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
- A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
- A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
- A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
- A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Drugs (8)
- Clazakizumab Interleukin-6 inhibitor
- Elsilimomab Interleukin-6 inhibitor
- MRA 003 US Interleukin-6 inhibitor
- Olokizumab Interleukin-6 inhibitor
- Pacibekitug Interleukin-6 inhibitor
- Siltuximab Interleukin-6 antagonist
- Sirukumab Interleukin-6 inhibitor
- Ziltivekimab Interleukin-6 binding agent; Interleukin-6 inhibitor